Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Story
TechCrunch [ai] · Artificial Intelligence
Join the conversation
Discuss the story with the TraceFeed community.
No comments yet. Be the first to add a perspective.